CD274 and small cell lung carcinoma: Nevertheless, large-scale international studies have demonstrated improved survival outcomes when combining PD-L1 inhibitors, such as durvalumab, with chemotherapy, highlighting the potential of chemoimmunotherapy approaches in SCLC (15).